MétaCan
Menu
Back to cohort
Record W2098103291 · doi:10.1345/aph.1d095

Fluoroquinolone AUIC Break Points and the Link to Bacterial Killing Rates: In Vitro Models

2003· letter· en· W2098103291 on OpenAlexaff
George G. Zhanel, Ayman Noreddin

Bibliographic record

VenueAnnals of Pharmacotherapy · 2003
Typeletter
Languageen
FieldMedicine
TopicAntibiotics Pharmacokinetics and Efficacy
Canadian institutionsUniversity of ManitobaHealth Sciences Centre
Fundersnot available
KeywordsMinimum inhibitory concentrationPharmacodynamicsStreptococcus pneumoniaeMedicineAntibioticsPseudomonas aeruginosaAntibiotic resistancePopulationPharmacokineticsPharmacologyMicrobiologyBacteriaBiology

Abstract

fetched live from OpenAlex

2003 September, Volume 37 ■ 1331 Schentag et al. 1 vigorously advocate the use of AUC24 / minimum inhibitory concentration (MIC) >125 for fluoroquinolones in order to achieve bacteriologic eradication against all target organisms and in all hosts. Their argument faces opposition from other groups in the field of pharmacodynamics.2 However, we welcome debate in the scientific arena because such dialogue opens the door for better understanding of fluoroquinolone pharmacokinetics/pharmacodynamics. Schentag et al.’s arguments attract attention to some important issues that necessitate further investigation and discussion concerning the way we design our in vitro modeling experiments, set study endpoints, define antibiotic break points, interpret results, and consider how antibiotic-resistant mutants develop within a bacterial population. Examination of and reflection on pharmacodynamic concepts may provide better approaches to designing in vitro and animal studies, as well as clinical trials, so that fluoroquinolones can be modeled to achieve maximum bacterial eradication (hopefully with acceptable toxicity) and optimal prevention of the development of bacterial resistance. We all agree that for fluoroquinolones, AUC24/MIC, and maximum concentration (Cmax )/MIC are the best predictors of microbiologic and, less so, clinical outcome. However, some important issues need to be considered to arrive at an optimal approach and draw conclusions from our in vitro modeling studies. First, it is time to realize that different fluoroquinolone AUC24/MIC (not simply AUC24/MIC >125) ratios are required for eradication and prevention of resistance in different organisms (e.g., Streptococcus pneumoniae, Pseudomonas aeruginosa). This has been well described previously3,4 and confirmed by MacGowan et al.5 As well, we need to realize that the immune system in an immunocompetent host may directly or indirectly lower the AUC24/MIC ratios required for bacterial eradication, potentially to varied degrees, depending on the organism. Second, since only the unbound fraction of the drug is biologically active,6,7 only the unbound (non-protein bound) fraction of the drug should be used in pharmacodynamic calculations. Thus, we should consider only the unbound drug AUC24/MIC and unbound drug Cmax/MIC pharmacodynamic predictors. This issue was made clear by Mouton et al.8 in their efforts to standardize pharmacokinetic/pharmacodynamic terminology for antiinfective drugs.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.002
metaresearch head score (Gemma)0.005
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Bench or experimental · Consensus signal: Bench or experimental
GenreCandidate signal: Other · Consensus signal: none
Teacher disagreement score0.007
Threshold uncertainty score0.020

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0020.005
Meta-epidemiology (narrow)0.0020.001
Meta-epidemiology (broad)0.0030.002
Bibliometrics0.0010.001
Science and technology studies0.0010.001
Scholarly communication0.0020.002
Open science0.0030.001
Research integrity0.0030.004
Insufficient payload (model declined to judge)0.0020.001

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.069
GPT teacher head0.362
Teacher spread0.294 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designBench or experimental
Domainnot available
GenreOther

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations0
Published2003
Admission routes1
Has abstractyes

Explore more

Same venueAnnals of PharmacotherapySame topicAntibiotics Pharmacokinetics and EfficacyFrench-language works237,207